| id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S9077 R31075 |
Tomson (Oxcarbazepine), 2015 | Perinatal death (during the first week after delivery from gestational week 24) | at least 1st trimester | prospective cohort | exposed to other treatment, sick | Adjustment: No | 1.05 [0.05;20.38] C | 0/240 3/1,763 | 3 | 240 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S9036 R30808 |
Artama (Oxcarbazepine) (Controls exposed to Lamotrigine, sick), 2013 | Perinatal death (stillbirth or early neonatal death (0–6 days of age)) | during pregnancy (anytime or not specified) | population based cohort retrospective | exposed to other treatment, sick excluded | Adjustment: No |
4.93 [0.28;86.83] C excluded (control group) |
7/532 0/173 | 7 | 532 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S9037 R30820 |
Artama (Oxcarbazepine) (Controls unexposed, disease free), 2013 | Perinatal death (stillbirth or early neonatal death (0–6 days of age)) | during pregnancy (anytime or not specified) | population based cohort retrospective | unexposed, disease free excluded | Adjustment: Yes |
2.55 [1.20;5.44] excluded (control group) |
7/532 3,543/721,948 | 3,550 | 532 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S9038 R30832 |
Artama (Oxcarbazepine) (Controls unexposed, sick), 2013 | Perinatal death (stillbirth or early neonatal death (0–6 days of age)) | during pregnancy (anytime or not specified) | population based cohort retrospective | unexposed, sick | Adjustment: Yes | 2.86 [1.01;8.08] | 7/532 10/1,800 | 17 | 532 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total | 2 studies | 2.56 [0.96;6.84] | 20 | 772 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1: Oxcarbazepine; 2: Oxcarbazepine) (Controls unexposed, sick;
Funnel plot not drawn. Less than 3 points.
Asymetry test p-value = NaN (by Egger's regression)
not enought points
Funnel plot not drawn. Less than 3 points.
excluded 9036, 9037